Edwards Lifesciences Corporation
EW
NYSE·Healthcare·Medical - Devices·Mkt cap $51.8B
$89.90
▲ +0.13%
P/E
51.67
Mkt Cap
$51.8B
52-Wk Range
$72.30–$96.29
52-Week Range
$72.30 - $96.29
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 12.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary medical technologies
- Strong research and development pipeline
- Global distribution network
- First-mover advantage in minimally invasive cardiac solutions
Bear Case
2 risks
- Average volatility.
- Premium valuation to Medical Devices peers
Growth
Stable outlook
Aging global population
Value
Premium valuation to Medical Devices peers
Momentum
Stable
+4.7% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EW right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 23, 2026
Reported EPS of $0.78 vs $0.74 consensus (+5.0% surprise). Revenue of $1.7B vs $1.7B expected (+2.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+5.0%
Revenue trend · last 8Q
—
+9%
+6%
+11%
+15%
+13%
+17%
+14%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.4B
$1.4B
$1.4B
$1.5B
$1.6B
$1.6B
$1.6B
$1.7B
Margins · last 8Q
Gross
77.6%
Operating
29.8%
Profit
13.9%
Wall Street consensus
12 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
—
Latest: UBS · Jul 28, 2026
vs Industry
How EW stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related